Primer Hastalarda Antiplatelet/Antikoagülan Kullanımı ve Prognozun Değerlendirilmesi COVID-19'lu Trombofili Hastaları

Basit Öğe Kaydı
dc.contributor.authorErkin, Alper
dc.contributor.authorYılmaz, Ayşe Çelik
dc.contributor.authorSunu, Cenk
dc.date.accessioned2025-03-24T19:48:19Z
dc.date.available2025-03-24T19:48:19Z
dc.date.issued2024
dc.departmentDüzce Üniversitesi
dc.description.abstractObjective: This study is aimed to investigate the relationship between inherited thrombophilia and COVID-19 symptoms and the outcomes of treatment strategies. Materials and Methods: This descriptive and retrospective study included patients who were followed up for thrombophilia in a training and research hospital. Data from 121 patients who had COVID-19 infection and those who met the inclusion criteria were collected through retrospective examination of medical records and telephone interviews using a data collection form developed by the researchers. The data obtained from the study was evaluated using descriptive and comparative statistical methods. Results: Among the patients diagnosed with COVID-19, 11.6% had severe clinical presentations requiring intensive care support. During COVID-19 infection, mostly no drug was preferred for treatment (51.2%), and the most preferred drug was acetylsalicylic acid (ASA) (33.1%). A total of 13 thromboembolic events occurred in 12 patients who were included in the study during and after COVID-19 infection. No thromboembolic events occurred in patients using warfarin or new-generation oral anticoagulants during COVID-19. There was no significant difference in thromboembolism complications among patients who did not use any medication, those who used ASA/clopidogrel, and those who used low molecular weight heparin during COVID-19 infection. The most common gene mutation in the study was plasminogen activator inhibitor-1 (PAI-1) mutation, and there was no statistically significant difference between PAI-1 gene mutation and new thrombotic events (p=0.988). Conclusion: COVID-19 infection was found to cause bilateral lung involvement with diffuse microthrombi in patients with genetic thrombophilia. No new thromboembolic events occurred in patients with thrombophilia using warfarin or new-generation oral anticoagulants.
dc.description.abstractObjective: This study is aimed to investigate the relationship between inherited thrombophilia and COVID-19 symptoms and the outcomes of treatment strategies. Materials and Methods: This descriptive and retrospective study included patients who were followed up for thrombophilia in a training and research hospital. Data from 121 patients who had COVID-19 infection and those who met the inclusion criteria were collected through retrospective examination of medical records and telephone interviews using a data collection form developed by the researchers. The data obtained from the study was evaluated using descriptive and comparative statistical methods. Results: Among the patients diagnosed with COVID-19, 11.6% had severe clinical presentations requiring intensive care support. During COVID-19 infection, mostly no drug was preferred for treatment (51.2%), and the most preferred drug was acetylsalicylic acid (ASA) (33.1%). A total of 13 thromboembolic events occurred in 12 patients who were included in the study during and after COVID-19 infection. No thromboembolic events occurred in patients using warfarin or new-generation oral anticoagulants during COVID-19. There was no significant difference in thromboembolism complications among patients who did not use any medication, those who used ASA/clopidogrel, and those who used low molecular weight heparin during COVID-19 infection. The most common gene mutation in the study was plasminogen activator inhibitor-1 (PAI-1) mutation, and there was no statistically significant difference between PAI-1 gene mutation and new thrombotic events (p=0.988). Conclusion: COVID-19 infection was found to cause bilateral lung involvement with diffuse microthrombi in patients with genetic thrombophilia. No new thromboembolic events occurred in patients with thrombophilia using warfarin or new-generation oral anticoagulants.
dc.identifier.doi10.31832/smj.1485712
dc.identifier.endpage427
dc.identifier.issn2146-409X
dc.identifier.issue4
dc.identifier.startpage420
dc.identifier.urihttps://doi.org/10.31832/smj.1485712
dc.identifier.urihttps://hdl.handle.net/20.500.12684/18887
dc.identifier.volume14
dc.language.isoen
dc.publisherSakarya Üniversitesi
dc.relation.ispartofSakarya Tıp Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_DergiPark_20250324
dc.subjectCoronavirus|Hereditary thrombophilia|Coagulation|Anticoagulation|Thrombosis|Coronavirus|Hereditary thrombophilia|Coagulation|Anticoagulation|Thrombosis
dc.titlePrimer Hastalarda Antiplatelet/Antikoagülan Kullanımı ve Prognozun Değerlendirilmesi COVID-19'lu Trombofili Hastaları
dc.title.alternativeEvaluation of Antiplatelet/Anticoagulant Use and Prognosis in Primary Thrombophilia Patients with COVID-19
dc.typeArticle

Dosyalar

Koleksiyon

Öksüz Yayınlar Koleksiyonu